

Francesco Fallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5989644/publications.pdf>

Version: 2024-02-01

197
papers

9,087
citations

41344

49
h-index

46799

89
g-index

201
all docs

201
docs citations

201
times ranked

6901
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and natural history of adrenal incidentalomas. <i>European Journal of Endocrinology</i> , 2003, 149, 273-285.	3.7	500
2	Somatic mutations in <i>ATP1A1</i> and <i>ATP2B3</i> lead to aldosterone-producing adenomas and secondary hypertension. <i>Nature Genetics</i> , 2013, 45, 440-444.	21.4	460
3	Prevalence and Characteristics of the Metabolic Syndrome in Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 454-459.	3.6	340
4	Cushing's syndrome. <i>Lancet</i> , The, 2001, 357, 783-791.	13.7	332
5	Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. <i>Nature Genetics</i> , 1992, 2, 66-74.	21.4	325
6	Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2014, 64, 354-361.	2.7	248
7	Prevalence, Clinical, and Molecular Correlates of <i>KCNJ5</i> Mutations in Primary Aldosteronism. <i>Hypertension</i> , 2012, 59, 592-598.	2.7	246
8	Risk factors and long-term outcome in pituitary-dependent Cushing's disease.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2647-2652.	3.6	226
9	Plasma adiponectin is decreased in nonalcoholic fatty liver disease. <i>European Journal of Endocrinology</i> , 2005, 152, 113-118.	3.7	223
10	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 520-526.	3.6	203
11	Comparison of Confirmatory Tests for the Diagnosis of Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2618-2623.	3.6	174
12	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 55-62.	3.6	160
13	Left ventricular structural and functional characteristics in Cushing's syndrome. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2275-2279.	2.8	159
14	Somatic <i>ATP1A1</i> , <i>ATP2B3</i> , and <i>KCNJ5</i> Mutations in Aldosterone-Producing Adenomas. <i>Hypertension</i> , 2014, 63, 188-195.	2.7	151
15	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1919-1928.	0.5	151
16	Anticoagulant Prophylaxis Markedly Reduces Thromboembolic Complications in Cushing's Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3662-3666.	3.6	141
17	Development of overt Cushing's syndrome in patients with adrenal incidentaloma. <i>European Journal of Endocrinology</i> , 2002, 146, 61-66.	3.7	140
18	Clinical Correlates of Major Depression in Cushing's Disease. <i>Psychopathology</i> , 1998, 31, 302-306.	1.5	134

#	ARTICLE	IF	CITATIONS
19	Diagnosis of Glucocorticoid-Remediable Aldosteronism in Primary Aldosteronism: Aldosterone Response to Dexamethasone and Long Polymerase Chain Reaction for Chimeric Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2573-2575.	3.6	121
20	Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2004, 150, 339-344.	3.7	95
21	Adiponectin and Insulin Sensitivity in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 2007, 20, 855-861.	2.0	94
22	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 641-649.	2.7	94
23	Psychological Assessment of Primary Aldosteronism: A Controlled Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E878-E883.	3.6	91
24	Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. <i>Hypertension</i> , 2015, 66, 149-157.	2.7	91
25	Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 646-653.	2.6	90
26	Persistent Psychological Distress in Patients Treated for Endocrine Disease. <i>Psychotherapy and Psychosomatics</i> , 2004, 73, 78-83.	8.8	82
27	Monogenic low renin hypertension. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 92-97.	7.1	78
28	Adrenocortical Carcinoma: Experience in 45 Patients. <i>Oncology</i> , 1997, 54, 490-496.	1.9	76
29	Psychological Aspects of Primary Aldosteronism. <i>Psychotherapy and Psychosomatics</i> , 2006, 75, 327-330.	8.8	74
30	CYP11B2 Gene Polymorphisms in Idiopathic Hyperaldosteronism. <i>Hypertension</i> , 2000, 35, 694-698.	2.7	72
31	Antiestrogens upregulate estrogen receptor β expression and inhibit adrenocortical H295R cell proliferation. <i>Journal of Molecular Endocrinology</i> , 2005, 35, 245-256.	2.5	72
32	Coronary Microvascular Dysfunction Induced by Primary Hyperparathyroidism is Restored After Parathyroidectomy. <i>Circulation</i> , 2012, 126, 1031-1039.	1.6	71
33	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. <i>International Journal of Cardiology: Hypertension</i> , 2020, 5, 100029.	2.2	69
34	High-salt diet increases glomerular ACE/ACE2 ratio leading to oxidative stress and kidney damage. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1793-1800.	0.7	63
35	Adiponectin, insulin resistance, and left ventricular structure in dipper and nondipper essential hypertensive patients. <i>American Journal of Hypertension</i> , 2005, 18, 30-35.	2.0	62
36	Psychosomatic aspects of Cushing's syndrome. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2010, 11, 95-104.	5.7	62

#	ARTICLE	IF	CITATIONS
37	Primary Aldosteronism and Metabolic Syndrome. <i>Hormone and Metabolic Research</i> , 2012, 44, 208-214.	1.5	62
38	Personality characteristics and quality of life in patients treated for Cushing's syndrome. <i>Clinical Endocrinology</i> , 2006, 64, 314-318.	2.4	60
39	Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. <i>European Journal of Endocrinology</i> , 2002, 147, 795-802.	3.7	58
40	Age-Related Changes in Glucocorticoid Fast Feedback Inhibition of Adrenocorticotropin in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1380-1383.	3.6	57
41	P450c17 Deficiency: Clinical and Molecular Characterization of Six Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1000-1007.	3.6	57
42	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 45-52.	2.2	57
43	Captopril Test Can Give Misleading Results in Patients With Suspect Primary Aldosteronism. <i>Hypertension</i> , 2007, 50, e26-7.	2.7	55
44	A Clinical Index for Rating Severity in Cushing's Syndrome. <i>Psychotherapy and Psychosomatics</i> , 2000, 69, 216-220.	8.8	51
45	Immunohistopathology and Steroid Profiles Associated With Biochemical Outcomes After Adrenalectomy for Unilateral Primary Aldosteronism. <i>Hypertension</i> , 2018, 72, 650-657.	2.7	51
46	Gender differences in predictors of intensive care units admission among COVID-19 patients: The results of the SARS-RAS study of the Italian Society of Hypertension. <i>PLoS ONE</i> , 2020, 15, e0237297.	2.5	51
47	Technetium-99m sestamibi scintigraphy and helical CT together in patients with primary hyperparathyroidism: a prospective clinical study. <i>British Journal of Radiology</i> , 2004, 77, 100-103.	2.2	50
48	Concurrent primary aldosteronism and subclinical cortisol hypersecretion. <i>Journal of Hypertension</i> , 2011, 29, 1773-1777.	0.5	50
49	Targeting Estrogen Receptor- α Reduces Adrenocortical Cancer (ACC) Cell Growth in Vitro and in Vivo: Potential Therapeutic Role of Selective Estrogen Receptor Modulators (SERMs) for ACC Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2238-E2250.	3.6	50
50	Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. <i>Journal of Human Hypertension</i> , 2004, 18, 47-51.	2.2	49
51	Progress in Primary Aldosteronism: Present Challenges and Perspectives. <i>Hormone and Metabolic Research</i> , 2010, 42, 374-381.	1.5	49
52	Left ventricular structural characteristics in Cushing's syndrome. <i>Journal of Human Hypertension</i> , 1994, 8, 509-13.	2.2	49
53	Psychosocial impairment in patients treated for pituitary disease: a controlled study. <i>Clinical Endocrinology</i> , 2007, 67, 719-726.	2.4	48
54	Ultrasound Evaluation of Carotid Artery in Primary Hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2096-2099.	3.6	47

#	ARTICLE	IF	CITATIONS
55	Genetic polymorphism of the renin-angiotensin-aldosterone system and arterial hypertension in the Italian population. <i>Journal of Hypertension</i> , 2003, 21, 1853-1860.	0.5	47
56	Impaired Potassium-Stimulated Aldosterone Production: A Possible Explanation for Normokalemic Glucocorticoid-Remediable Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1507-1510.	3.6	46
57	Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells. <i>Journal of Endocrinology</i> , 1998, 159, 373-380.	2.6	45
58	Life events in the pathogenesis of hyperprolactinemia. <i>European Journal of Endocrinology</i> , 2004, 151, 61-65.	3.7	45
59	Primary Aldosteronism and Obstructive Sleep Apnea. <i>Hypertension</i> , 2019, 74, 1532-1540.	2.7	45
60	Effect of Angiotensin II and Converting Enzyme Inhibitor (Captopril) on Blood Pressure, Plasma Renin Activity and Aldosterone in Primary Aldosteronism. <i>Clinical Science</i> , 1981, 61, 289s-293s.	0.0	44
61	Effect of surgical treatment on hypertension in Cushing's syndrome. <i>American Journal of Hypertension</i> , 1996, 9, 77-80.	2.0	43
62	Expression of aromatase and estrogen receptors in human adrenocortical tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 181-191.	2.8	43
63	GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2015, 6, 19190-19203.	1.8	43
64	Potassium-Stimulated Angiotensin Release from Superfused Adrenal Capsules and Enzymatically Dispersed Cells of the Zona Glomerulosa*. <i>Endocrinology</i> , 1991, 129, 823-831.	2.8	41
65	Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. <i>Journal of Internal Medicine</i> , 1993, 234, 595-598.	6.0	41
66	Nonalcoholic Fatty Liver Disease in Primary Aldosteronism: A Pilot Study. <i>American Journal of Hypertension</i> , 2010, 23, 2-5.	2.0	41
67	Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. <i>Pituitary</i> , 2000, 3, 55-59.	2.9	40
68	Analysis of Insulin Sensitivity in Adipose Tissue of Patients with Primary Aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4037-4042.	3.6	40
69	A NEW FAMILY WITH DEXAMETHASONE-SUPPRESSIBLE HYPERALDOSTERONISM: ALDOSTERONE UNRESPONSIVENESS TO ANGIOTENSIN II. <i>Clinical Endocrinology</i> , 1985, 22, 777-785.	2.4	39
70	MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 AND ADRENAL LESIONS. <i>Journal of Urology</i> , 2001, 166, 24-27.	0.4	39
71	Primary aldosteronism, a major form of low renin hypertension: from screening to diagnosis. <i>Trends in Endocrinology and Metabolism</i> , 2008, 19, 104-108.	7.1	38
72	ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. <i>Journal of Human Hypertension</i> , 2016, 30, 374-378.	2.2	38

#	ARTICLE	IF	CITATIONS
73	Mineralocorticoid hypertension due to a nasal spray containing 9 β -fluoroprednisolone. American Journal of Medicine, 1981, 71, 352-357.	1.5	36
74	Recovery of Bone Mineral Density after Surgical Cure, but not by Ketoconazole Treatment, in Cushing's Syndrome. Osteoporosis International, 2001, 12, 956-960.	3.1	35
75	Cardiovascular autonomic function in Cushing's syndrome. Journal of Endocrinological Investigation, 2009, 32, 41-45.	3.3	35
76	Differential expression of menin in sporadic pituitary adenomas.. Endocrine-Related Cancer, 2004, 11, 333-344.	3.1	34
77	Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients. Journal of Hypertension, 2008, 26, 2191-2197.	0.5	34
78	Pharmacologic Management of Cushing Syndrome. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 87-94.	1.8	33
79	24-Hour Blood Pressure Profile in Addison's Disease. American Journal of Hypertension, 1994, 7, 1105-1109.	2.0	32
80	Slow-Release Lanreotide Treatment in Acromegaly: Effects on Quality of Life. Psychotherapy and Psychosomatics, 1999, 68, 165-167.	8.8	32
81	Effects of taxol on the human NCI-H295 adrenocortical carcinoma cell line. Endocrine Research, 1996, 22, 709-715.	1.2	31
82	Inactivation of the p16 Tumor Suppressor Gene in Adrenocortical Tumors ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2776-2779.	3.6	31
83	Blood Pressure in Patients with Primary Aldosteronism Is Influenced by Bradykinin B ₂ Receptor and β -Adducin Gene Polymorphisms. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3337-3343.	3.6	30
84	Paclitaxel Is an Effective Antiproliferative Agent on the Human NCI-H295 Adrenocortical Carcinoma Cell Line. Chemotherapy, 1998, 44, 129-134.	1.6	28
85	Selective Venous Sampling in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome. Neuroendocrinology, 1992, 55, 264-268.	2.5	27
86	Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency.. Journal of Clinical Endocrinology and Metabolism, 1994, 79, 452-455.	3.6	27
87	Coexistence of Aldosteronoma and Contralateral Nonfunctioning Adrenal Adenoma in Primary Aldosteronism. American Journal of Hypertension, 1997, 10, 476-478.	2.0	27
88	The metabolic syndrome in primary aldosteronism. Current Diabetes Reports, 2008, 8, 42-47.	4.2	27
89	Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics, 2014, 15, 1643-1652.	1.3	27
90	Excess dietary sodium and inadequate potassium intake by hypertensive patients in Italy. Journal of Hypertension, 2014, 32, 48-56.	0.5	26

#	ARTICLE	IF	CITATIONS
91	1 α ,25-Dihydroxyvitamin D ₃ inhibits the human H295R cell proliferation by cell cycle arrest: A model for a protective role of vitamin D receptor against adrenocortical cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 140, 26-33.	2.5	26
92	Mutations in CYP11B1 Gene Converting 11 β -Hydroxylase into an Aldosterone-Producing Enzyme Are Not Present in Aldosterone-Producing Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4228-4231.	3.6	25
93	Adrenal Venous Samplingâ€“Guided Adrenalectomy Rates in Primary Aldosteronism: Results of an International Cohort (AVSTAT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1400-e1407.	3.6	25
94	Circadian Blood Pressure Patterns and Life Stress. <i>Psychotherapy and Psychosomatics</i> , 2002, 71, 350-356.	8.8	24
95	Ambulatory arterial stiffness indices and non-alcoholic fatty liver disease in essential hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 389-393.	2.6	23
96	Coronary microvascular function in patients with Cushingâ€™s syndrome. <i>Endocrine</i> , 2013, 43, 206-213.	2.3	23
97	Methylation Status of Vitamin D Receptor Gene Promoter in Benign and Malignant Adrenal Tumors. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-7.	1.5	23
98	The metabolic syndrome in primary aldosteronism. <i>Current Hypertension Reports</i> , 2007, 9, 106-111.	3.5	22
99	Should we evaluate for cardiovascular disease in patients with Cushingâ€™s syndrome?. <i>Clinical Endocrinology</i> , 2009, 71, 768-771.	2.4	22
100	Histopathological and genetic characterization of aldosterone-producing adenomas with concurrent subclinical cortisol hypersecretion: a case series. <i>Endocrine</i> , 2017, 58, 503-512.	2.3	22
101	Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. <i>Frontiers in Endocrinology</i> , 2020, 11, 554.	3.5	21
102	Effect of Metoclopramide on Plasma Aldosterone in Normal Subjects, Primary Aldosteronism and Hypopituitarism. <i>Hormone and Metabolic Research</i> , 1981, 13, 464-467.	1.5	20
103	Regression of cardiac abnormalities after replacement therapy in Addison's disease. <i>European Journal of Endocrinology</i> , 1999, 140, 425-428.	3.7	20
104	Aldosterone effects on glomerular structure and function. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 730-738.	1.7	20
105	Determinants of healing among patients with coronavirus disease 2019: the results of the SARS-RAS study of the Italian Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 376-380.	0.5	20
106	In Situ Analysis of Human Menin in Normal and Neoplastic Pancreatic Tissues: Evidence for Differential Expression in Exocrine and Endocrine Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3893-3901.	3.6	19
107	The role of 21-hydroxylase in the pathogenesis of adrenal masses: Review of the literature and focus on our own experience. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 615-623.	3.3	19
108	Renal Artery Denervation for Treating Resistant Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2012, 19, 237-244.	2.2	19

#	ARTICLE	IF	CITATIONS
109	Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis. <i>Pituitary</i> , 2018, 21, 653-662.	2.9	19
110	Aldosterone-producing adenomas do not contain glucocorticoid-remediable aldosteronism chimeric gene duplications.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4310-4312.	3.6	18
111	Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. <i>Molecular and Cellular Endocrinology</i> , 2012, 355, 162-168.	3.2	18
112	Steroids and hypertension. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991, 40, 35-44.	2.5	17
113	Overnight dexamethasone suppression of cortisol is associated with radiocholesterol uptake patterns in adrenal incidentalomas. <i>European Journal of Endocrinology</i> , 2001, 145, 223-224.	3.7	17
114	Left ventricular geometry and 24-h blood pressure profile in Cushingâ€™s syndrome. <i>Endocrine</i> , 2017, 55, 547-554.	2.3	17
115	Psychological Distress and Quality of Life in Endocrine Disease. <i>Psychotherapy and Psychosomatics</i> , 1990, 54, 140-144.	8.8	16
116	Zona fasciculata-like histotype and aldosterone response to upright posture are not related in aldosterone-producing adenomas. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1998, 106, 74-78.	1.2	16
117	Shift from Connâ€™s syndrome to Cushingâ€™s syndrome in a recurrent adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2005, 153, 629-636.	3.7	16
118	Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues. <i>Pituitary</i> , 2015, 18, 525-534.	2.9	16
119	Ambulatory arterial stiffness indexes in acromegaly. <i>European Journal of Endocrinology</i> , 2012, 166, 199-205.	3.7	15
120	Sleep disorders and cognitive dysfunction in acromegaly. <i>Endocrine</i> , 2019, 66, 634-641.	2.3	15
121	Effect of Naloxone on the Adrenal Cortex in Primary Aldosteronism. <i>American Journal of Hypertension</i> , 1988, 1, 280-282.	2.0	13
122	Juxtaglomerular Cell Tumor of the Kidney. <i>Clinical and Experimental Hypertension</i> , 1994, 16, 41-53.	1.3	13
123	Effect of Octreotide on 24-h Blood Pressure Profile in Acromegaly. <i>American Journal of Hypertension</i> , 1998, 11, 591-596.	2.0	13
124	Low serum 25-hydroxyvitamin D levels are associated with left ventricular hypertrophy in essential hypertension. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 871-876.	2.6	13
125	Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy. <i>Atherosclerosis</i> , 2018, 269, 100-105.	0.8	13
126	Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism. <i>Endocrine</i> , 2018, 60, 129-137.	2.3	13

#	ARTICLE	IF	CITATIONS
127	The effects of mitotane and 1 α ,25-dihydroxyvitamin D3 on Wnt/beta-catenin signaling in human adrenocortical carcinoma cells. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 357-367.	3.3	13
128	DNA Methylation of Steroidogenic Enzymes in Benign Adrenocortical Tumors: New Insights in Aldosterone-Producing Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4605-e4615.	3.6	13
129	Dexamethasone-suppressible hyperaldosteronism: Pathophysiology, clinical aspects, and new insights into the pathogenesis. <i>Klinische Wochenschrift</i> , 1987, 65, 437-444.	0.6	12
130	Inhibition of Pituitary β -Endorphin by ACTH and Glucocorticoids. <i>Neuroendocrinology</i> , 1990, 51, 561-564.	2.5	12
131	New Aspects of Mineralocorticoid Hypertension. <i>Hormone Research</i> , 1990, 34, 175-180.	1.8	12
132	Disseminated nocardiosis in a patient with Cushing's syndrome. <i>Journal of Endocrinological Investigation</i> , 1994, 17, 443-445.	3.3	12
133	Hyperaldosteronism: Screening and Diagnostic Tests. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2016, 23, 69-72.	2.2	12
134	Ambulatory Arterial Stiffness Indexes in Cushing's Syndrome. <i>Hormone and Metabolic Research</i> , 2017, 49, 214-220.	1.5	12
135	Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1909-1921.	4.1	12
136	Ovarian tumors secreting insulin. <i>Endocrine</i> , 2015, 49, 611-619.	2.3	11
137	Prevalence and determinants of resistant hypertension in a sample of patients followed in Italian hypertension centers: results from the MINISAL-SIIA study program. <i>Journal of Human Hypertension</i> , 2016, 30, 703-708.	2.2	11
138	Hyperinsulinemia and obese phenotype differently influence blood pressure in young normotensive patients with polycystic ovary syndrome. <i>Endocrine</i> , 2017, 55, 625-634.	2.3	11
139	Bradykinin B2Receptor Gene C-58T Polymorphism and Insulin Resistance. A Study on Obese Patients. <i>Hormone and Metabolic Research</i> , 2004, 36, 243-246.	1.5	10
140	Biochemical Markers of Endothelial Activation in Primary Hyperparathyroidism. <i>Hormone and Metabolic Research</i> , 2006, 38, 125-129.	1.5	10
141	Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing's syndrome. <i>Endocrine</i> , 2014, 47, 557-563.	2.3	10
142	Ambulatory Blood Pressure Monitoring-Derived Short-Term Blood Pressure Variability in Primary Aldosteronism. <i>Journal of Clinical Hypertension</i> , 2015, 17, 603-608.	2.0	10
143	Effect of Captopril on Blood Pressure and on the Renin-Angiotensin-Aldosterone System in Coarctation of the Aorta. <i>Clinical and Experimental Hypertension</i> , 1983, 5, 321-328.	0.3	9
144	Adrenal incidentaloma in pregnancy: Clinical, molecular and immunohistochemical findings. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 459-463.	3.3	9

#	ARTICLE	IF	CITATIONS
145	Aldosterone does not Modify Gene Expression in Human Endothelial Cells. <i>Hormone and Metabolic Research</i> , 2012, 44, 234-238.	1.5	9
146	Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2013, 20, 33-37.	2.2	9
147	Plasma renin activity in coarctation of the aorta before and after surgical correction.. <i>Heart</i> , 1978, 40, 1415-1418.	2.9	8
148	Effect of $\hat{\pm}$ -Human Atrial Natriuretic Peptide in Low Renin Essential Hypertension and Primary Aldosteronism. <i>Clinical and Experimental Hypertension</i> , 1987, 9, 1505-1513.	0.3	8
149	Conceptual basis and methodology of the SOPHIA study. <i>Pharmacogenomics</i> , 2007, 8, 1497-1509.	1.3	8
150	Aldosterone, Calcium, and Hypertension. <i>American Journal of Nephrology</i> , 1986, 6, 33-39.	3.1	7
151	Patterns of ACTH Response to oCRH in Cushing's Disease: Correlation with Histological/Immunocytochemical Findings. <i>Neuroendocrinology</i> , 1994, 60, 237-242.	2.5	7
152	Abnormality of aldosterone and cortisol late pathways in glucocorticoid-remediable aldosteronism.. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 772-774.	3.6	7
153	Retention of heterozygosity at chromosome 7p22 and 11q13 in aldosterone-producing tumours of patients with familial hyperaldosteronism not remediable by glucocorticoids. <i>Journal of Human Hypertension</i> , 2004, 18, 829-830.	2.2	7
154	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 29-36.	2.2	7
155	Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth. <i>Cells</i> , 2017, 6, 42.	4.1	7
156	New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. <i>Microvascular Research</i> , 2020, 128, 103940.	2.5	7
157	Isolated R171Q amino acid change in <i>MEN1</i> gene: polymorphism or mutation?. <i>Clinical Endocrinology</i> , 2008, 69, 511-511.	2.4	6
158	Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study. <i>Nutrients</i> , 2022, 14, 2683.	4.1	6
159	The early diagnosis of multiple endocrine neoplasia type 1 (MEN 1): A case report. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 878-882.	3.3	5
160	Insulin signaling in adipose tissue of patients with primary aldosteronism. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 86-89.	3.3	5
161	Abnormality of aldosterone and cortisol late pathways in glucocorticoid-remediable aldosteronism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 772-774.	3.6	5
162	$\hat{\pm}$ -h-ANP injection in normals, low renin hypertension and primary aldosteronism. <i>The Journal of Steroid Biochemistry</i> , 1987, 27, 935-940.	1.1	4

#	ARTICLE	IF	CITATIONS
163	EFFECTS OF NALOXONE ON THE PITUITARY-ADRENAL AXIS IN PATIENTS WITH DEXAMETHASONE-SUPPRESSIBLE HYPERALDOSTERONISM. <i>Clinical Endocrinology</i> , 1987, 26, 163-168.	2.4	4
164	Concomitant Release of Renin, Angiotensin I, and Angiotensin II During Supervision of Human Juxtaglomerular Cell Tumor. <i>American Journal of Hypertension</i> , 1992, 5, 566-569.	2.0	4
165	Anxiety sensitivity in essential hypertension. <i>Stress and Health</i> , 1992, 8, 113-115.	0.5	4
166	Genetic Forms of Primary Aldosteronism. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2007, 14, 75-81.	2.2	4
167	Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 135-142.	2.2	4
168	Effect of metergoline on the aldosterone-stimulating properties of metoclopramide. <i>The Journal of Steroid Biochemistry</i> , 1983, 19, 531-536.	1.1	3
169	Percutaneous Transluminal Renal Angioplasty in the Treatment of Renovascular Hypertension in Children. <i>Clinical and Experimental Hypertension</i> , 1986, 8, 887-891.	0.3	3
170	Effects of naloxone on adrenal cortex regulation in patients with primary aldosteronism. <i>Journal of Endocrinological Investigation</i> , 1988, 11, 261-265.	3.3	3
171	Comparison of the antihypertensive and renal effects of tertatolol and nadolol in hypertensive patients with mild renal impairment. <i>European Journal of Clinical Pharmacology</i> , 1991, 40, 309-311.	1.9	3
172	The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from Rimonabant In Obesity (RIO) trials. <i>International Congress Series</i> , 2007, 1303, 146-154.	0.2	3
173	Autocrine-Paracrine Role of Endothelin-1 in the Regulation of Aldosterone Synthase Expression and Intracellular Ca ²⁺ in Human Adrenocortical Carcinoma NCI-H295 Cells. <i>Endocrinology</i> , 1997, 138, 4421-4426.	2.8	3
174	Effect of Captopril on Inactive Renin and Contact Phase of Coagulation System. <i>Clinical and Experimental Hypertension</i> , 1982, 4, 2425-2434.	0.3	2
175	Resistance to captopril in hypertension of coarctation of the aorta. <i>International Journal of Cardiology</i> , 1985, 9, 111-113.	1.7	2
176	Use of quantitative ultrasound of the hand phalanges in the diagnosis of two different osteoporotic syndromes: Cushing's syndrome and postmenopausal osteoporosis. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 510-515.	3.3	2
177	Metabolic syndrome and primary aldosteronism: time for reappraisal?. <i>Journal of Human Hypertension</i> , 2010, 24, 623-624.	2.2	2
178	Evolution of computed tomography-detectable adrenal nodules in patients with bilateral primary aldosteronism. <i>Endocrine</i> , 2016, 54, 826-829.	2.3	2
179	Plasma mineralocorticoid activity, mineralocorticoid receptors and intracellular electrolytes in patients with dexamethasone-suppressible hyperaldosteronism (DSH). <i>European Journal of Endocrinology</i> , 1986, 113, S179-S180.	3.7	2
180	Potential therapeutic effects of ritanserin in Cushing's disease. <i>JAMA - Journal of the American Medical Association</i> , 1992, 267, 1073.	7.4	2

#	ARTICLE	IF	CITATIONS
181	Captopril-induced changes on active and inactive renin in a patient with factor XII congenital deficiency. Research in Experimental Medicine, 1985, 185, 217-220.	0.7	1
182	Erythrocyte Na ⁺ -Li ⁺ countertransport and blood viscosity in arterial hypertension. Research in Experimental Medicine, 1986, 186, 71-77.	0.7	1
183	Aldosterone and Pressor Responses to Angiotensin II in Primary Hyperparathyroidism. Hormone and Metabolic Research, 1989, 21, 457-459.	1.5	1
184	Pro-gamma-MSH levels in various disorders of pituitary-adrenal axis. Journal of Endocrinological Investigation, 1990, 13, 29-33.	3.3	1
185	Aldosteroneâ€“adrenomedullin: a new feedback regulation in blood vessels?. Journal of Hypertension, 2002, 20, 1081-1082.	0.5	1
186	A case of nephrotic syndrome hidden by Cushingâ€™s disease. Endocrine, 2015, 48, 722-724.	2.3	1
187	Sudden death with massive hemoptysis from aortobronchial fistula. Cardiovascular Pathology, 2020, 44, 107158.	1.6	1
188	Insulin Sensitivity and Glucose Resistance in Elderly Hypertensive Patients. American Journal of Hypertension, 2006, 19, 103-103.	2.0	0
189	Microalbuminuria, Endothelial Dysfunction and Cardiovascular Risk: Study in Bartterâ€™s/Gitelmanâ€™s Syndromes and Relevance for Hypertension. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 145-196.	2.2	0
190	The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from rimonabant in obesity (RIO) trials. Clinical Cornerstone, 2007, 8, 82.	0.7	0
191	Reply to letter to the editor â€œBlood pressure variability in primary hyperparathyroidism: more data neededâ€• Endocrine, 2018, 60, 199-200.	2.3	0
192	Title is missing!. , 2020, 15, e0237297.		0
193	Title is missing!. , 2020, 15, e0237297.		0
194	Title is missing!. , 2020, 15, e0237297.		0
195	Title is missing!. , 2020, 15, e0237297.		0
196	Title is missing!. , 2020, 15, e0237297.		0
197	Title is missing!. , 2020, 15, e0237297.		0